Gland Pharma Limited has informed the Exchange regarding Appointment of Ms RVR and Associates as Secretarial Auditor of the company w.e.f. April 01, 2025.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma's board met on May 20, 2025 and approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Statutory auditor Deloitte Haskins & Sells issued an unmodified (clean) opinion on the financials. The board recommended a final dividend of Rs. 18 per equity share (1800%) on a face value of Rs. 1, with the record date set as August 14, 2025 and payment within 30 days of the AGM. The 47th AGM is scheduled for August 28, 2025 via video conferencing. Additionally, M/s. RVR & Associates was appointed as Secretarial Auditor for a five-year term starting April 1, 2025, subject to shareholder approval. Certain governance policies (Material Subsidiaries, Related Party Transactions, Insider Trading, and Whistle Blower) were also updated to align with recent SEBI regulation amendments.
A clean audit opinion and a strong final dividend of Rs. 18 per share signal financial health and shareholder-friendly capital returns, which are likely to be viewed positively by investors. The governance-related changes are routine compliance updates with no material business impact.